Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy

Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma

Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round. The funds will support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of SDT in patients with newly diagnosed glioblastoma (GBM) – one of the most aggressive and deadly forms of brain cancer.

Backed by leading healthcare investors, the round was co-led by HealthQuest Capital and Samsara BioCapital with participation from existing investors OrbiMed and Action Potential Venture Capital. In addition, venture investors committed to transforming cancer care participated, including BrightEdge, the impact investment and innovation arm of the American Cancer Society, the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society, and Sontag Innovation Fund, a subsidiary of The Sontag Foundation.

“The complex and diffuse nature of glioblastomas has long hindered therapeutic innovation,” said Conrad Wang M.D., Partner at HealthQuest Capital. “Alpheus’ sonodynamic therapy represents a novel, non-invasive whole brain approach with compelling early data. This investment reflects our commitment to advancing transformative technologies that seek to fill critical gaps in patient unmet needs.”

Alpheus’ platform delivers non-thermal, tumor-selective therapy activated by low-intensity diffuse ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA). Without the need for imaging or sedation, this combination selectively targets and destroys cancer cells across the entire brain hemisphere. This novel treatment option is performed in an outpatient setting. Promising early results from two studies highlight the potential of SDT therapy in both newly diagnosed and recurrent glioblastoma patients.

“This investment is a key inflection point for Alpheus and the glioblastoma community – advancing sonodynamic therapy from promise to clinical validation,” commented Vijay Agarwal, MD, FAANS, FCNS, President and CEO of Alpheus Medical. “With this support, we are poised to generate pivotal evidence that could help establish a new standard of care for newly diagnosed brain tumors.”

About Alpheus Medical, Inc.

Alpheus Medical is a private, clinical-stage oncology company developing a groundbreaking, non-invasive treatment for solid tumors utilizing sonodynamic therapy (SDT). Its proprietary platform combines Low-Intensity Diffuse Ultrasound (LIDU™) with oral 5-aminolevulinic acid (5-ALA), a sensitizing agent that selectively accumulates in tumor cells. This targeted approach aims to destroy cancer cells while sparing healthy tissue. Alpheus collaborates with global leaders in neuro-oncology and is supported by top healthcare investors and the venture vehicles of nonprofit organizations focused on cancer. Learn more at www.alpheusmedical.com.

---

Disclaimer: This press release was originally published by Alpheus Medical, Inc.

---